Navigation Links
KellBenx Secures Worldwide Agreement With Cedars-Sinai Medical Center for Biomarker Technology to Predict Premature Births
Date:4/18/2011

NEW YORK, April 18, 2011 /PRNewswire/ -- KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has signed an exclusive options agreement with Cedars-Sinai Medical Center to research a new blood test that could predict the risk of premature births early in pregnancy – or even before women become pregnant. Preterm delivery (PTD) is the leading cause of infant mortality in the world, causing up to 85 percent of all newborn deaths. KellBenx' worldwide license for Cedars-Sinai's diagnostic biomarker technology is the first step towards developing a marketable, minimally invasive test that can predict PTD and allow patients and doctors to make informed decisions about pregnancy in advance.

PTD occurs in about one-eighth of all pregnancies in the United States – more than a half million cases a year – but the primary current diagnostic testing for PTD risk is used only in the third trimester, to predict whether the patient will go into labor within the next two weeks.

"There is currently no test to predict the risk of PTD in future pregnancies of women who are not yet pregnant, and there is a tremendous need for such a test to identify women at high risk," said Hassan Bennani, MD., CEO of KellBenx. "With this agreement, KellBenx can begin the research process to turn this biomarker technology into a simple blood test that will help physicians focus on preventative strategies in these women and improve pregnancy outcomes. This is early-stage technology, but it has exciting possibilities for potentially reducing infant mortality."

The technology consists of a triple assay of biomarkers  that can measure a blood sample obtained from the prospective mother either before pregnancy or in the early stages to identify the potential for PTD.  The test could be repeated multiple times during pregnancy to track potential changes in risk as the pregnancy progresses.

About KellBenx

Founded in 2010, KellBenx, Inc. is a privately-held biotechnology company based in New York City. KellBenx is developing high value, innovative tests that leverage the ability to extract clinically relevant information from blood.  Our focus is to improve women's healthcare and one of our first tests is in the area of non-invasive prenatal diagnosis (NIPD) for genetic disorders. For more information, please call 631.643.2614 or visit www.kellbenx.com.


'/>"/>
SOURCE KellBenx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WNDM Secures Additional International Sales; $150 K in New Orders for 2011
2. BioNeutral Group Secures Three Initial Trial Orders for its Ogiene™ Odor Neutralizer & Multi-Purpose Cleaner Product Line
3. ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction
4. Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank
5. SeraCare Life Sciences Secures $20 Million Credit Facilities
6. Medizone International Secures $10,000,000 Funding Commitment
7. aTyr Pharma Secures $23M Financing From Top Tier Venture Investor
8. Omeros Secures $40 Million Committed Equity Financing Facility
9. SPO Medical Secures Agreement in Sleep Apnea Market
10. Biolaxy Secures IND Approval for Oral Insulin
11. Osteotech Secures 10-Year Tissue Supply Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , ... March 30, 2017 , ... ... vaccines/immunology and general medicine, recently announced the hiring of Bruce Wakeman into the ... the position of Associate Vice President, Proposals & Marketing. , Bruce brings Accelovance ...
(Date:3/30/2017)... , March 30, 2017  Jazz Pharmaceuticals plc ... has entered into license agreements with Nippon Shinyaku, Co., ... ™ (cytarabine and daunorubicin liposome injection), or CPX-351, ... the terms of the agreements, Nippon Shinyaku will receive ... in Japan in return for ...
(Date:3/29/2017)... VA (PRWEB) , ... March 29, 2017 , ... ... wearable patch comprising multiple separable adhesive layers, as issued by the U.S. Patent ... layers as it applies to combining electronics and health monitoring. This invention will ...
(Date:3/29/2017)... Inc. (NASDAQ: VRML), a bio-analytical solutions company focused ... the fourth quarter and full year ended December ... year for us with our first clinical utility ... reimbursement progress with Medicare, positive medical policy coverage ... cleared our 2 nd generation product Overa ...
Breaking Biology Technology:
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... the prestigious international IAIR Award for the most innovative high security ePassport ... ... Maldives Immigration Controller General, Mr. ... on the right) have received the IAIR award for the "Most innovative ...
(Date:3/23/2017)... 2017 The report "Gesture Recognition and Touchless Sensing Market ... - Global Forecast to 2022", published by MarketsandMarkets, the market is expected to ... between 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):